Literature DB >> 23242510

Novel mutations in cyclin-dependent kinase-like 5 (CDKL5) gene in Indian cases of Rett syndrome.

Dhanjit Kumar Das1, Bhakti Mehta, Shyla R Menon, Sarbani Raha, Vrajesh Udani.   

Abstract

Rett syndrome is a severe neurodevelopmental disorder, almost exclusively affecting females and characterized by a wide spectrum of clinical manifestations. Both the classic and atypical forms of Rett syndrome are primarily due to mutations in the methyl-CpG-binding protein 2 (MECP2) gene. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene have been identified in patients with atypical Rett syndrome, X-linked infantile spasms sharing common features of generally early-onset seizures and mental retardation. CDKL5 is known as serine/threonine protein kinase 9 (STK9) and is mapped to the Xp22 region. It has a conserved serine/threonine kinase domain within its amino terminus and a large C-terminal region. Disease-causing mutations are distributed in both the amino terminal domain and in the large C-terminal domain. We have screened the CDKL5 gene in 44 patients with atypical Rett syndrome who had tested negative for MECP2 gene mutations and have identified 6 sequence variants, out of which three were novel and three known mutations. Two of these novel mutations p.V966I and p.A1011V were missense and p.H589H a silent mutation. Other known mutations identified were p.V999M, p.Q791P and p.T734A. Sequence homology for all the mutations revealed that the two mutations (p.Q791P and p.T734A) were conserved across species. This indicated the importance of these residues in structure and function of the protein. The damaging effects of these mutations were analysed in silico using PolyPhen-2 online software. The PolyPhen-2 scores of p.Q791P and p.T734A were 0.998 and 0.48, revealing that these mutations could be deleterious and might have potential functional effect. All other mutations had a low score suggesting that they might not alter the activity of CDKL5. We have also analysed the position of the mutations in the CDKL5 protein and found that all the mutations were present in the C-terminal domain of the protein. The C-terminal domain is required for cellular localization through protein-protein interaction; any mutations in this domain might alter this function of the protein. This is the first report from India showing the mutation in CDKL5 gene in Indian cases of Rett syndrome. Our study emphasizes the role of CDKL5 mutation screening in cases of atypical Rett syndrome with congenital seizure variant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242510     DOI: 10.1007/s12017-012-8212-z

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  23 in total

1.  The clinical pattern of the Rett syndrome.

Authors:  F Hanefeld
Journal:  Brain Dev       Date:  1985       Impact factor: 1.961

2.  Analysis of Hungarian patients with Rett syndrome phenotype for MECP2, CDKL5 and FOXG1 gene mutations.

Authors:  Kinga Hadzsiev; Noemi Polgar; Judit Bene; Katalin Komlosi; Judit Karteszi; Katalin Hollody; Gyorgy Kosztolanyi; Alessandra Renieri; Bela Melegh
Journal:  J Hum Genet       Date:  2010-12-16       Impact factor: 3.172

3.  Two affected boys in a Rett syndrome family: clinical and molecular findings.

Authors:  L Villard; A Kpebe; C Cardoso; P J Chelly; P M Tardieu; M Fontes
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

4.  Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.

Authors:  Jiong Tao; Hilde Van Esch; M Hagedorn-Greiwe; Kirsten Hoffmann; Bettina Moser; Martine Raynaud; Jürgen Sperner; Jean-Pierre Fryns; Eberhard Schwinger; Jozef Gécz; Hans-Hilger Ropers; Vera M Kalscheuer
Journal:  Am J Hum Genet       Date:  2004-12       Impact factor: 11.025

5.  Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location.

Authors:  J P Cheadle; H Gill; N Fleming; J Maynard; A Kerr; H Leonard; M Krawczak; D N Cooper; S Lynch; N Thomas; H Hughes; M Hulten; D Ravine; J R Sampson; A Clarke
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

6.  Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships.

Authors:  Nadia Bahi-Buisson; Nathalie Villeneuve; Emilie Caietta; Aurélia Jacquette; Helene Maurey; Gert Matthijs; Hilde Van Esch; Andrée Delahaye; Anne Moncla; Mathieu Milh; Flore Zufferey; Bertrand Diebold; Thierry Bienvenu
Journal:  Am J Med Genet A       Date:  2012-06-07       Impact factor: 2.802

7.  CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.

Authors:  N Bahi-Buisson; T Bienvenu
Journal:  Mol Syndromol       Date:  2011-09-13

8.  CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail.

Authors:  Laura Rusconi; Lisa Salvatoni; Laura Giudici; Ilaria Bertani; Charlotte Kilstrup-Nielsen; Vania Broccoli; Nicoletta Landsberger
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

9.  Rett variants: a suggested model for inclusion criteria.

Authors:  B A Hagberg; O H Skjeldal
Journal:  Pediatr Neurol       Date:  1994-07       Impact factor: 3.372

10.  CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.

Authors:  E Scala; F Ariani; F Mari; R Caselli; C Pescucci; I Longo; I Meloni; D Giachino; M Bruttini; G Hayek; M Zappella; A Renieri
Journal:  J Med Genet       Date:  2005-02       Impact factor: 6.318

View more
  8 in total

Review 1.  Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.

Authors:  Neha Sami; Vijay Kumar; Asimul Islam; Sher Ali; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Mol Neurobiol       Date:  2016-08-20       Impact factor: 5.590

2.  Mutations in the C-terminus of CDKL5: proceed with caution.

Authors:  Bertrand Diebold; Chloé Delépine; Svetlana Gataullina; Andrée Delahaye; Juliette Nectoux; Thierry Bienvenu
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

3.  Molecular aberration studies in cases of idiopathic mental retardation: An update.

Authors:  Dhanjit Kumar Das
Journal:  Indian J Hum Genet       Date:  2013-04

4.  Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.

Authors:  Ying Zhao; Xiaoying Zhang; Xinhua Bao; Qingping Zhang; Jingjing Zhang; Guangna Cao; Jie Zhang; Jiarui Li; Liping Wei; Hong Pan; Xiru Wu
Journal:  BMC Med Genet       Date:  2014-02-25       Impact factor: 2.103

5.  A non-syndromic intellectual disability associated with a de novo microdeletion at 7q and 18p, microduplication at Xp, and 18q partial trisomy detected using chromosomal microarray analysis approach.

Authors:  Irene Plaza Pinto; Lysa Bernardes Minasi; Alex Silva da Cruz; Aldaires Vieira de Melo; Damiana Míriam da Cruz E Cunha; Rodrigo Roncato Pereira; Cristiano Luiz Ribeiro; Claudio Carlos da Silva; Daniela de Melo E Silva; Aparecido Divino da Cruz
Journal:  Mol Cytogenet       Date:  2014-06-27       Impact factor: 2.009

6.  Screening for intellectual disability using high-resolution CMA technology in a retrospective cohort from Central Brazil.

Authors:  Rodrigo Roncato Pereira; Irene Plaza Pinto; Lysa Bernardes Minasi; Aldaires Vieira de Melo; Damiana Mirian da Cruz e Cunha; Alex Silva Cruz; Cristiano Luiz Ribeiro; Cláudio Carlos da Silva; Daniela de Melo e Silva; Aparecido Divino da Cruz
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

7.  Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome.

Authors:  Meghana Mangatt; Kingsley Wong; Barbara Anderson; Amy Epstein; Stuart Hodgetts; Helen Leonard; Jenny Downs
Journal:  Orphanet J Rare Dis       Date:  2016-04-14       Impact factor: 4.123

8.  CDKL5 promotes proliferation, migration, and chemotherapeutic drug resistance of glioma cells via activation of the PI3K/AKT signaling pathway.

Authors:  Zhenfu Jiang; Tongtong Gong; Hong Wei
Journal:  FEBS Open Bio       Date:  2020-01-21       Impact factor: 2.792

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.